Share on LinkedInShare on LinkedIn

ARTICLE · 09 JANUARY 2018

China's Recent Development On Granting Biological Sequence Claims

Life sciences and biotechnology are widely regarded as one of the most promising frontier technologies for the coming decades.

ChinaIntellectual Property

Life sciences and biotechnology are widely regarded as one of the most promising frontier technologies for the coming decades. Patent protection is at the core of the business for biotechnology companies, and for them, it is also crucial to understand that there exist strong differences amongst jurisdictions concerning what is considered as patentable subject matter, what disclosure is required, and what claim breath is allowed.

One distinctive feature in biotechnology is to define claims by biological sequences (such as nucleotide sequences, amino acid sequences). In China, however, whether these claims are supported in view of examples provided in the description is a prominent issue. A recent case from Supreme People's Court may shed some lights on the Chinese examination inquiry. This short article discussed the case, as well as Chinese practice.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from